Dice Therapeutics Experiences Stellar 62% Gain On Phase 1 Trial Data And Launches $250 Million Offering

Dice Therapeutics

Discusses the Phase 1 result release, stock offering that was announced and some market commentary Biopharma company Dice Therapeutics (NASDAQ:DICE) was once of the markets top gainers on Tuesday as the stock opened and jumped more than 86% higher to $45.99 after the company released initial Phase 1 trial results for its DC-806 lead oral […]